Eli Lilly re-invests GLP-1 cash into pipeline
The constructive case argued for Eli Lilly is that aggressive M&A using GLP-1 cash flows strengthens long-term pipeline optionality outside core weight-loss drugs.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.